Choose TEPMETKO for lasting efficacy first-line and beyond, confirmed with >18 months' follow-up*^1–3

Overview of results in the VISION trial

In 111 patients with METex14 skipping NSCLC detected by tissue biopsy, first-line TEPMETKO achieved:**¹

ORR

58.6%

95% CI: 48.8–67.8

mDOR

46.4

MONTHS

95% CI: 15.2–NE

mPFS

15.9

Months

95% CI: 11.0–49.7

mOS

29.7

months

95% CI: 18.8–NE

TEPMETKO vs. capmatinib

TEPMETKO may offer significantly increased mDOR vs. capmatinib²

A matching-adjusted indirect comparison (MAIC) of TEPMETKO vs. capmatinib has shown improved mDOR, mOS and mPFS²

TEPMETKO vs. capmatinib efficacy outcomes in treatment-naïve patients:

mDOR

mOS

mPFS

TEPMETKO

(ESS=83.3)

46.4

MONTHS

95% CI: 46.4–NE

29.7

MONTHS

95% CI: 14.2–NE

22.0

MONTHS

95% CI: 11.3–NE

Capmatinib

(n=28)

12.6

MONTHS

95% CI: 5.6–NE

20.7

MONTHS

95% CI: 12.5–NE

12.3

MONTHS

95% CI: 8.2–NE

The same trend was observed in previously treated patients²

VISION trial: efficacy in the tissue biopsy subgroup

Tissue biopsy; ‘gold standard’ biopsy method^4,5

In 111 patients with METex14 skipping NSCLC detected by tissue biopsy, first-line TEPMETKO achieved:

ORR¹

58.6%

95% CI: 48.8–67.8

mDOR¹

46.4

MONTHS

95% CI: 15.2–NE

mPFS¹

15.9

Months

95% CI: 11.0–49.7

mOS¹

29.7

months

95% CI: 18.8–NE

As in the first line, TEPMETKO achieved robust efficacy in previously treated patients which was confirmed with 18 months' follow-up:

ORR¹

49.5%

95% CI: 39.2–59.8

mDOR¹

12.4

MONTHS

95% CI: 8.3–18.0

mPFS¹

11.5

Months

95% CI: 8.2–14.7

mOS¹

20.4

MONTHS

95% CI: 17.0–25.5

VISION trial: efficacy in the liquid biopsy subgroup

Liquid biopsy; typically higher tumor burden^5,6

In the VISION trial, efficacy over time differed between biopsy subgroups, in line with the liquid biopsy subgroup having a worse prognosis due to a higher tumor burden^5,6

TEPMETKO gave patients access to prognosis-transforming targeted therapy via non-invasive (blood draw) detection of alternation^1,4

Treatment-naïve patients

ORR¹

58.9%

95% CI: 48.4–68.9

mDOR¹

19.4

MONTHS

95% CI: 8.3–NE

mPFS¹

10.3

MONTHS

95% CI: 8.0–16.5

mOS¹

17.6

MONTHS

95% CI: 10.4–23.7

Previously treated patients

ORR¹

43.4%

95% CI: 32.5–54.7

mDOR¹

12.4

MONTHS

95% CI: 8.4–33.6

mPFS¹

8.2

MONTHS

95% CI: 5.7–11

mOS¹

16.2

MONTHS

95% CI: 12.0–21.0

With TEPMETKO, help give your patients more moments that matter

TEPMETKO vs. other treatments

Early use of targeted TEPMETKO therapy unlocked lasting efficacy^7,8

TEPMETKO vs. real-world outcomes
TEPMETKO vs. standard treatment

In treatment-naïve patients, a matched indirect treatment comparison^†  of TEPMETKO vs. real-world outcomes on (chemo-)immunotherapy has confirmed the OS and PFS benefit of using TEPMETKO first-line⁸

Choose TEPMETKO early to target aggressive METex14 skipping NSCLC^7,9

TEPMETKO

29.7

MONTHS’ mOS

(HR 0.64; p=0.05)

vs.

IO monotherapy

18.9

MONTHS’ mOS

TEPMETKO delivered meaningful long-term clinical efficacy in the VISION study, exceeding that seen with standard treatment in prior line^†7

Choose TEPMETKO early for your hard-to-treat patients with METex14 skipping NSCLC^7,9

TEPMETKO

12.6

MONTHS’ mDOR

Second-line or later

vs.

Prior regimen

6.0

MONTHS’ mDOR

Platinum-based CT, IO monotherapy, or IO + platinum-based CT

Intracranial disease control

Even in patients with METex14 skipping NSCLC and brain metastases, TEPMETKO demonstrated robust intracranial outcomes¹

Results reinforced by a substantial and meaningful subgroup of almost 60 patients^††1

77% intracranial disease control (n=44/57)¹⁰
67% intracranial response (n=10/15)^‡10
8.5 months’ (95% CI: 6.8–19.4) intracranial mPFS (n=57)¹⁰

Supported by 25% blood-brain barrier penetration in preclinical studies¹¹

BASELINE

1 brain lesion 11.1 mm

WEEK 6

Brain lesion PR  5.8 mm (-47.8%)

WEEK 36

Brain lesion CR  0 mm (-100%)

Consider TEPMETKO as a treatment option for your patients  with METex14 skipping NSCLC and concurrent brain metastases¹²

With TEPMETKO, give your patients more moments that matter

3–4% of your patients with NSCLC may have METex14 skipping^9,13,14

Explore the importance of timely targeted therapy for your NSCLC patients

Learn more about the unmet need

Explore the VISION trial

Learn more about the patient characteristics, efficacy outcomes and design of VISION, a single-arm, open-label, multicenter, non-randomized, multi-cohort study that analyzed patients with METex14 skipping NSCLC (N=313)^1,13

Learn more about the VISION trial

TEPMETKO demonstrated a manageable safety profile that maintained QoL**^1,10,15–17

Most common AEs were mild to moderate¹⁰

Learn more about safety, dosing and QoL

*Cohort A follow-up >35 months; Cohort C follow-up >18 months; median follow-up of Cohorts A+C 32.6 months¹
**Data shown are from Cohorts A+C^{1

†}This is not a direct head-to-head comparison study
^††All lines combined; tissue and liquid biopsy¹⁰
^‡Excludes non-target brain lesions¹⁰

Abbreviations

AE, adverse event; CI, confidence interval; CR, complete response; CT, chemotherapy; ESS, effective sample size; HR, hazard ratio; IO, immunotherapy; MAIC, matching-adjusted indirect comparison; mDOR, median duration of reponse; METex14, mesenchymal epithelial transition factor exon 14; mOS median overall survival; mPFS, median progression-free survival; MRI, magnetic resonance imaging; NSCLC; non-small cell lung cancer; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; QoL, quality of life

References

Mazieres J et al. JAMA Oncol 2023; 9:1260−1266.
Pfeiffer BM et al. Presented at: IASLC World Conference on Lung Cancer (WCLC) 2023; 9−12 September 2023; Virtually and Singapore (Poster no. 1312).
TEPMETKO® (tepotinib) [prescribing information], EMD Serono, Inc., Rockland, MA; 2024.
Di Capua D et al. Cancers 2021; 13:3923..
Rolfo C et al. Presented at: European Society for Medical Oncology (ESMO) 2023; 20–24 October 2023; Madrid, Spain (Poster no. 1382P)..
Le X et al. Presented at: IASLC World Conference on Lung Cancer (WCLC) 2023; 9−12 September 2023; Singapore (Presentation no. OA21.06).
Viteri S et al. Presented at: European Society for Medical Oncology (ESMO) 2023; 20–24 October 2023; Madrid, Spain (Poster no. 1380P).
Christopoulos P et al. Presented at: European Society for Medical Oncology (ESMO) 2023; 20–24 October 2023; Madrid, Spain (Poster no. 1381P).
Tong JH et al. Clin Cancer Res 2016; 22:3048–3056.
Mazieres J et al. JAMA Oncol 2023; 9:1260–1266 (supplementary appendix 2).
Thomas M et al. Presented at: IASLC World Conference on Lung Cancer (WCLC) 2022; 6–9 August 2022; Vienna, Austria (Presentation no. OA03.05).
Le X et al. Clin Cancer Res 2022; 28:1117–1126.
Paik PK et al. N Engl J Med 2020; 383:931–943.
Salgia R. Mol Cancer Ther 2017; 16:555–565.
Paik PK et al. Presented virtually at: American Society of Clinical Oncology (ASCO) Annual Meeting 2023; 2–6 June 2023; Chicago, IL, USA (Abstract no. 9060).
Veillon R et al. Clin Lung Cancer 2022; 23:320–332.
Ahn L et al. Clin J Oncol Nurs 2022; 26:543–551.

This website is an international information resource intended only for healthcare professionals from outside the European Economic Area (EEA), the US, Puerto Rico and Canada who are interested in information on TEPMETKO. The information on this website contains educational and promotional material. By clicking on 'I'm a healthcare professional' you are declaring and confirming that are you a healthcare professional and have read and understood this.

GL-TEP-00506 | April 2025

This website is an international information resource intended only for Healthcare Professionals from outside the European Economic Area (EEA), the US, Puerto Rico
and Canada who are interested in information on TEPMETKO.

Choose TEPMETKO for lasting efficacy first-line and beyond, confirmed with >18 months' follow-up*1–3

Overview of results in the VISION trial

ORR

58.6%

mDOR

46.4

MONTHS

mPFS

15.9

Months

mOS

29.7

months

TEPMETKO vs. capmatinib

TEPMETKO may offer significantly increased mDOR vs. capmatinib2

TEPMETKO vs. capmatinib efficacy outcomes in treatment-naïve patients:

mDOR

mOS

mPFS

TEPMETKO

46.4

95% CI: 46.4–NE

29.7

95% CI: 14.2–NE

22.0

95% CI: 11.3–NE

Capmatinib

12.6

95% CI: 5.6–NE

20.7

95% CI: 12.5–NE

12.3

95% CI: 8.2–NE

VISION trial: efficacy in the tissue biopsy subgroup

Tissue biopsy; ‘gold standard’ biopsy method4,5

ORR1

58.6%

mDOR1

46.4

MONTHS

mPFS1

15.9

Months

mOS1

29.7

months

ORR1

49.5%

mDOR1

12.4

MONTHS

mPFS1

11.5

Months

mOS1

20.4

MONTHS

VISION trial: efficacy in the liquid biopsy subgroup

Liquid biopsy; typically higher tumor burden5,6

ORR1

58.9%

mDOR1

19.4

MONTHS

mPFS1

10.3

MONTHS

mOS1

17.6

MONTHS

ORR1

43.4%

mDOR1

12.4

MONTHS

mPFS1

8.2

MONTHS

mOS1

16.2

Choose TEPMETKO for lasting efficacy first-line and beyond, confirmed with >18 months' follow-up*^1–3

TEPMETKO may offer significantly increased mDOR vs. capmatinib²

Tissue biopsy; ‘gold standard’ biopsy method^4,5

ORR¹

mDOR¹

mPFS¹

mOS¹

ORR¹

mDOR¹

mPFS¹

mOS¹

Liquid biopsy; typically higher tumor burden^5,6

ORR¹

mDOR¹

mPFS¹

mOS¹

ORR¹

mDOR¹

mPFS¹

mOS¹

Even in patients with METex14 skipping NSCLC and brain metastases, TEPMETKO demonstrated robust intracranial outcomes¹

3–4% of your patients with NSCLC may have METex14 skipping^9,13,14

TEPMETKO demonstrated a manageable safety profile that maintained QoL**^1,10,15–17